Product nameAnti-Cytokeratin 5 antibody - Cytoskeleton Marker
See all Cytokeratin 5 primary antibodies
DescriptionRabbit polyclonal to Cytokeratin 5 - Cytoskeleton Marker
Specificityab53121 detects endogenous levels of total Cytokeratin 5 protein.
Tested applicationsSuitable for: ELISA, IHC-P, Flow Cyt, ICC/IF, IHC-FoFr, IHC-Fr, WBmore details
Species reactivityReacts with: Mouse, Rat, Human, Pig
A synthetic peptide derived from human Cytokeratin 5.
- HepG2 cell extracts and human breast carcinoma tissue.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
Without Mg+2 and Ca+2
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab53121 was affinity purified from rabbit antiserum by affinity chromatography using epitope specific immunogen.
Our Abpromise guarantee covers the use of ab53121 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration. PubMed: 24648397
ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.
|ICC/IF||Use a concentration of 1 µg/ml.|
|IHC-FoFr||Use at an assay dependent concentration. PubMed: 21278345|
|IHC-Fr||Use at an assay dependent concentration. PubMed: 22308455|
|WB||1/300 - 1/1000. Detects a band of approximately 62 kDa (predicted molecular weight: 62 kDa).|
Involvement in diseaseDefects in KRT5 are a cause of epidermolysis bullosa simplex Dowling-Meara type (DM-EBS) [MIM:131760]. DM-EBS is a severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement.
Defects in KRT5 are the cause of epidermolysis bullosa simplex with migratory circinate erythema (EBSMCE) [MIM:609352]. EBSMCE is a form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands, feet, and legs but spare nails, ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS, with no evidence of tonofilament clumping.
Defects in KRT5 are a cause of epidermolysis bullosa simplex Weber-Cockayne type (WC-EBS) [MIM:131800]. WC-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.
Defects in KRT5 are a cause of epidermolysis bullosa simplex Koebner type (K-EBS) [MIM:131900]. K-EBS is a form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, althought it is less severe.
Defects in KRT5 are the cause of epidermolysis bullosa simplex with mottled pigmentation (MP-EBS) [MIM:131960]. MP-EBS is a form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and 'mottled' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules.
Defects in KRT5 are the cause of Dowling-Degos disease (DDD) [MIM:179850]; also known as Dowling-Degos-Kitamura disease or reticulate acropigmentation of Kitamura. DDD is an autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails.
Sequence similaritiesBelongs to the intermediate filament family.
- Information by UniProt
- 58 kDa cytokeratin antibody
- CK-5 antibody
- CK5 antibody
ab53121 at 1/50 dilution staining Cytokeratin 5 in human breast carcinoma by Immunohistochemistry, Paraffin embedded tissue, in the absence and presence of the immunising peptide.
ICC/IF image of ab53121 stained MCF7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab53121, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
All lanes : Anti-Cytokeratin 5 antibody - Cytoskeleton Marker (ab53121) at 1/300 dilution
Lane 1 : HepG2 cell extract
Lane 2 : HepG2 cell extract with immunising peptide
Predicted band size: 62 kDa
Observed band size: 62 kDa
This product has been referenced in:
- Kim SW et al. Transcriptome analysis after PPAR? activation in human meibomian gland epithelial cells (hMGEC). Ocul Surf N/A:N/A (2019). Read more (PubMed: 30742991) »
- Romanova OA et al. Non-woven bilayered biodegradable chitosan-gelatin-polylactide scaffold for bioengineering of tracheal epithelium. Cell Prolif 52:e12598 (2019). Read more (PubMed: 30900363) »